^
Association details:
| Biomarker: | MET amplification + EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib
Published date:
07/31/2020
Excerpt:
...MET amplification induced osimertinib resistance...MET amplification might induce heterogeneous responses to osimertinib in EGFR-mutated NSCLC. Further investigations on mutated EGFR and amplified MET might lead to the development of effective therapies.
DOI:
10.1111/cas.14593
